Toll Free: 1-888-928-9744
Published: Nov, 2013 | Pages:
243 | Publisher: GMR Data
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GMR Data forecast that the global cancer drugs and treatments market will reach $143.7bn by 2023. GMR Data’s latest report 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ explains just how this market will experience growth over the medium and long term. The report also highlights forecast for the next 5 and 10 years, so that you and your company can make specific long term plans. Don’t let your competitors get the head-start on you, order this report today. Have you seen the recent news on Cancer Drugs? - Merck’s new cancer drug kept more than 4 of 5 melanoma patients alive for a year - Biopharma Alliances will be needed For Cancer Drugs in the cost conscious future – Forbes - EU approval for Bayer’s prostate cancer drug - Sanofi ditches late-stage bone marrow cancer drug The Anti-cancer treatment market is already worth $77.4bn (GMR Data) and continues to be one of the largest and fastest growing areas for new drug development – can you afford not to be involved? Should you and your company be capturing a greater market share? Essential facts examined in this report 1) Across 2013, 15 new molecular entities were approved by the FDA; out of which seven were for Oncology. 2) Currently targeted therapies dominate the oncology pipeline, followed by chemotherapy. 3) Immunotherapy drugs are gaining increasing amounts of attention due to fewer expected side effects. Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report. Discover exactly what the industry leaders are doing TODAY - Within GMR Data’s 'The Cancer Drugs & Treatments Market - Data, Analysis & Forecasts to 2023’ we analyse the key cancer drugs and treatments in the market currently and how they will perform across the next decade. Our study focuses on the individual revenues of the top 25 anti-cancer agents. With variable patents and the threat of generics, how will these key cancer drugs fare across the next decade? – ONLY THIS UNIQUE REPORT WILL TELL YOU • Rituxan • Herceptin • Avastin • Gleevec • Revlimid • Alimta • Velcade PLUS – In-depth country analysis – Discover which countries and regions will drive the oncology drugs market to 2023? The US spent $322bn on healthcare in 2011, GMR Data estimate that the US spent $31.8bn in the oncology market in 2012, capturing 40.5% of the market. 2nd to the US was Japan; spending $8.9bn in 2012, capturing 11.2%. The European mainstays of the pharmaceutical sector; the UK, Germany, France, Spain & Italy equated to 25% of the global oncology market in 2012. But how will these country’s markets develop? This report will tell you - TODAY Exclusive Industry sourced information, not available anywhere else As well as primary and secondary research sources, GMR Data have interviewed leading cancer specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else. This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Cancer Drugs. This report will arm you with all you and your company require to develop, price, launch and market a cancer drug. With over 240+ pages, and over 270+ charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.
Chapter 1 Executive Summary 1.1 Cancer Drugs Market Review - How will the cancer drugs market grow to 2023? What is it worth today? Why? 1.2 Chapter Breakdown 1.3 Research and Analysis Methods - As well as the usual research tools; company fililngs, press releases, analyst knowledge, we also interviewed key decision makers / scientific researchers to gain an overall picture of the cancer drugs market. Chapter 2 Types of Cancer; Causes, symptoms and global prevalance of the key cancers affecting the worlds population 2.1 Blood Cancer Types and Symptoms 2.1.2 Blood Cancer- Global Market 2.1.3 Blood Cancer- Causes and Risk Factors 2.2 Bone Cancer Types and Symptoms 2.2.1 Bone Cancer- Global Market 2.2.2 Bone Cancer Causes and Risk Factors 2.3 Brain Cancer Types and Symptoms 2.3.1 Brain Cancer Market- Global 2.3.2 Brain Cancer- Causes and Risk Factors 2.4 Breast Cancer Types and Symptoms 2.4.1 Breast Cancer Market- Global 2.4.2 Breast Cancer Causes and Risk factors 2.5 Digestive/ Gastrointestinal Cancer Types and Symptoms 2.5.1 Gastrointestinal Cancer Market- Global 2.5.2 Gastrointestinal Cancer- Causes and Risk Factors 2.6 Endocrine Cancers Types and Symptoms 2.6.1 Endocrine Cancer Market- Global 2.6.2 Endocrine Cancer- Causes and Risk Factors 2.7 Eye Cancer Types and Symptoms 2.7.1 Eye Cancer Market- Global 2.7.2 Eye Cancer Causes and Risk Factors 2.8 Genitourinary Cancers Types & Symptoms 2.8.1 Genitourinary Cancer Market – Global 2.8.2 Genitourinary Cancers - Causes and Risk Factors 2.9 Gynaecologic Cancers Types & Symptoms 2.9.1 Gynaecologic Cancer Market – Global 2.9.2 Gynaecologic Cancers - Causes and Risk Factors 2.10 Head & Neck Cancers Types & Symptoms 2.10.1 Head and Neck Cancer Market – Global 2.10.2 Head and Neck Cancer - Causes and Risk Factors 2.11 Respiratory/Lung Cancers Types & Symptoms 2.11.1 Respiratory Cancer Market – Global 2.11.2 Respiratory Cancer - Causes and Risk Factors 2.12 Skin Cancers Types & Symptoms 2.12.1 Skin Cancer – Global Market 2.12.2 Skin Cancer - Causes and Risk Factors 2.13 Worldwide Cancer Facts and Statistics 2.13.1 Cancer Incidence Facts & Statistics 2.13.2 Cancer Mortality and Survival Facts & Statistics Chapter 3 Cancer; Causes & Effects - Which factors effect the causes of cancers, globally. 3.1 Genetic Causes 3.2 Tobacco & Smoking 3.3 Physical Activities and Eating Habits 3.4 Viral Infections 3.5 Bacterial Infections 3.6 Age 3.7 Carcinogens Chapter 4 Cancer Treatment Types & Side Effects 4.1 Surgery 4.1.1 Potential Side effects of Surgery 4.2 Chemotherapy - How will the mainstay of cancer treatment fair Vs. newer types of cancer treatment? 4.2.1 Major Side effects of Chemotherapy 4.3 Radiation Therapy 4.3.1 Major Side effects of Radiation Therapy 4.4 Targeted Therapy - Precision drugs; the future or too expensive for global use? 4.4.1 Major Side effects of Targeted Therapy 4.5 Immunotherapy (Biologic Therapy) - Great potential for some cancers, but lacking the wide range of other treatments? 4.5.1 Major Side effects of Immunotherapy 4.6 Hormonal Therapy 4.6.1 Major Side effects of Hormone Therapy 4.7 Hyperthermia 4.7.1 Major Side effects of Hyperthermia 4.8 Stem Cell Transplant 4.8.1 Major Side effects of Stem Cell Transplant 4.9 Other Therapies 4.9.1 Photodynamic Therapy 4.9.2 Side effects of Photodynamic Therapy 4.9.3 Laser Treatment 4.9.4 Side effects of Laser Treatment Chapter 5 Cancer Therapies / Drugs Market Forecast 5.1 Global Targeted Therapy Market – 2013 -2023 5.1.1 Rituxan/MabThera by Roche - Rituxan faces the end of patent exclusivity in key areas across our forecast period; how greatly will this effect global revenue? 5.1.2 Herceptin (Trastuzumab) by Roche - How will biosimilars affect Herceptin's bottom line in the near to mid future? 5.1.3 Avastin (Bevacizumab) by Roche - What potential does Avastin have to enter the combination therapies market in the US/European markets? 5.1.4 Gleevec (imatinib) by Novartis - Gleeva generated $4.7bn across 2012, how will this figure fair to 2023 5.1.5 Velcade (Bortezomib) by Takeda (Millennium) and J&J - GMR Data forecast negative growth for Velcade to 2023, how & why? 5.1.6 Tarceva (Erlotinib) by Roche - GMR Data forecast strong growth to 2018, which factors contribute to this forecast? 5.1.7 Sutent (Sunitinib) by Pfizer - Sutent revenue increased by 4% between 2011 and 2012, find out why here. 5.1.8 Sprycel (dasatinib) by Bristol Myers Squibb Sprycel's non-US sales revenue increased by 22% bewtween 2011 & 2012 ; find out which regions have driven this growth. 5.1.9 Nexavar (Sorafenib) by Bayer and Onyx - How hard will the (expected) loss of patent exclusivity hit Nexavar's bottom line across our forecast period? 5.1.10 Tasigna (Nilotinib) by Novartis - Tasigna is forecast to show strong growth throughout the forecast period - how & why? 5.1.11 Afinitor / Votubia (Everolimus) by Novartis 5.1.12 Xgeva (Denosumab) by Amgen 5.1.13 Yervoy (ipilimumab) by Bristol-Myers Squibb 5.1.14 Erbitux (cetuximab) by Bristol-Myers Squibb 5.2 Global Chemotherapy Market – 2013 -2023 5.2.1 Alimta (Pemetrexed) by Eli Lilly 5.2.2 Xeloda (capecitabine) by Roche 5.2.3 Eloxatin (oxaliplatin) by Sanofi-Aventis 5.2.4 Temodar / Temodal (temozolomide) by Merck & Co. 5.2.5 Vidaza (azacitidine) by Celgene 5.2.6 Taxotere (docetaxel) by Sanofi-Aventis 5.2.7 Treanda (bendamustine hydrochloride) by Teva Pharmaceuticals 5.3 Global Immunotherapy (Biological therapy) Market – 2013 -2023 5.3.1 Revlimid (lenalidomide) by Celgene 5.3.2 Gardasil (Human Papillomavirus Quadrivalent) by Merck 5.3.3 Zometa (zoledronate) by Novartis 5.4 Global Hormone Therapy Market – 2013 -2023 5.4.1 Faslodex (Fulvestrant) Injection by AstraZeneca 5.4.2 Zoladex (Goserelin acetate implant) by AstraZeneca 5.4.3 Arimidex (anastrozole) by AstraZeneca 5.4.4 Casodex (bicalutamide) by AstraZeneca 5.4.5 Sandostatin (octreotide acetate) by Novartis Chapter 6 Cancer R&D Pipeline and Drugs 6.1 R&D Pipeline 6.1.1 Oncology Drugs; Recent Approvals 6.1.2 Late Stage Cancer Drugs 6.1.3 Key Experimental Cancer Drugs Pipeline 6.1.4 Oncology Drug Pipeline – Cancer Drugs Failures Chapter 7 Major Trends & Challenges in the Global Cancer Drugs Market 7.1 Major Trends 7.1.1 Personalised Medication 7.1.2 Increasing Cancer Threat In Low & Middle Income Countries 7.1.3 Antibody Drug Conjugates (ADC) 7.1.4 Combination Therapy 7.1.5 Key Collaborations and Alliances 7.1.6 New Drug Development 7.1.7 Immunotherapy – to be the next Industry Driver 7.2 Major Challenges 7.2.1 Expensive Treatment 7.2.2 Biosimilars Competition 7.2.3 Generic Competition 7.2.4 Severe Side Effects of Cancer Care Treatment 7.2.5 Regulatory Hurdles in Cancer Drug Approvals Chapter 8 Regional Landscape – The Key Global Cancer Drug Markets 8.1. The US Oncology Market to 2023 8.2. The UK Oncology Market to 2023 8.3. France Oncology Market to 2023 8.4 The German Oncology Market to 2023 8.5 The Spanish Oncology Market to 2023 8.6 The Italian Oncology Market to 2023 8.7 The Japanese Oncology Market to 2023 8.8 The Rest of the World Oncology Market to 2023 Chapter 9 Major Players in the Oncology Market 9.1 Amgen 9.2 Ariad Pharmaceutical 9.3 ASTELLAS PHARMA 9.4 AstraZeneca 9.5 Bayer healthcare pharmaceuticals 9.6 Boehringer Ingelheim 9.7 Bristol-Myers Squibb 9.8 Celgene 9.9 Eisai Co., Ltd. 9.10 Eli Lilly & Co 9.11 ImClone Systems Inc. (a subsidiary of Eli Lilly & Co) 9.12 Exelixis 9.13 GlaxoSmithKline 9.14 Merck & Co 9.15 Millennium Pharmaceuticals (Subsidiary of Takeda Oncology Company) 9.16 Novartis Pharmaceuticals 9.17 Onyx Pharmaceuticals 9.18 Pfizer Inc. 9.19 Roche 9.20 Sanofi 9.21 Teva Pharmaceuticals Industries Chapter 10 Expert Opinion 10.1 Dr John Marshall, Clinical Director of Oncology, Georgetown University Hospital 10.2 Dr Anderson Ryan, Senior Group Leader at Gray Institute of Radiation, Oncology and Biology, at the University of Oxford 10.3 Dr Ben Anderson, Professor of Surgery at the University of Washington & Chair of the Breast Health Global Initiative
List of Tables Table 18.104.22.168 Major Drugs in Blood Cancer Market Table 22.214.171.124 Major Bone Cancer Drugs in the Market Table 126.96.36.199 Major Brain Cancer Drugs in Market Table 2.1.4a Breast Cancer Incidences in US & UK Table 2.1.4b Major Breast Cancer Drugs in Market Table 2.1.5 Major Gastrointestinal Cancer Drugs in Market Table 2.1.6 Major Endocrine Cancer Drugs in Market Table 2.1.7 Major Eye Cancer drugs In the Market Table 2.1.8 Major Genitourinary Cancers Cancer drugs In the Market Table 2.1.9 Major Gynaecologic Cancer drugs In the Market Table 2.1.10a Head & Neck Incidences in Asian Region - 2008 Table 2.1.10b Major Head and Neck Cancer Drugs in the Market Table 2.1.11 Major Respiratory Cancer Drugs in the Market Table 2.1.12 Major Skin Cancer Drugs in the Market Table 4.1 Type of Cancer Surgeries Table 4.3 Type of Radiation Therapy Table 4.5 Types of Immunotherapy Table 4.6 Types of Hormone Therapy Table 4.7 Type or Ways of Hyperthermia Treatment Table 4.8 Type of Stem Cell Transplant Table 4.9.2 Type of Laser Treatments Table 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012 Table 5.1.b: Global Targeted Therapy Market for Cancer Treatment: 2013-2023 Table 5.1.1.a: 2011 - 2012 Rituxan Sales Geographic Breakdown ($ bn) Table 5.1.1.b: Rituxan Oncology Sales: 2008-2012 Table 5.1.1.c: Rituxan Sales & Forecast: 2013-2023 Table 5.1.2.a: Herceptin Sales: 2008-2012 Table 5.1.2.b: 2011 - 2012 Herceptin Sales Geographic Breakdown ($ bn) Table 5.1.2.c: Herceptin Sales & Forecast: 2013-2023 Table 5.1.3.a: Avastin Sales: 2008-2012 Table 5.1.3.b: 2011 - 2012 Avastin Sales Geographic Breakdown ($ bn) Table 5.1.3.c: Avastin Sales & Forecast: 2013-2023 Table 5.1.4.a: Gleevec Sales: 2008-2012 Table 5.1.4.b: 2011 - 2012 Gleevec Sales Geographic Breakdown ($ bn) Table 5.1.4.c: Gleevec Sales & Forecast: 2013-2023 Table 5.1.5.a: Velcade Sales: 2008-2012 Table 5.1.5.b: 2011 - 2012 Velcade Sales Geographic Breakdown ($ bn) Table 5.1.5.c: Velcade Sales & Forecast: 2013-2023 Table 5.1.6.a: Tarceva Sales: 2008-2012 Table 5.1.6.b: 2011 - 2012 Tarceva Sales Geographic Breakdown ($/m) Table 5.1.6.c: Tarceva Sales & Forecast: 2013-2023 Table 5.1.7.a: Sutent Sales: 2008-2012 Table 5.1.7.b: Sutent Sales & Forecast: 2013-2023 Table 5.1.8.a: Sprycel Sales: 2008-2012 Table 5.1.8.b: 2011 - 2012 Sprycel Sales Geographic Breakdown ($ m) Table 5.1.8.c: Sprycel Sales & Forecast: 2013-2023 Table 5.1.9.a: Nexavar Sales: 2008-2012 ($/bn) Table 5.1.9.b: Nexavar Sales & Forecast: 2013-2023 Table 5.1.10.a: Tasigna Sales: 2008-2012 Table 5.1.10.b: 2011 - 2012 Tasigna Sales Geographic Breakdown ($ m) Table 5.1.10.c: Tasigna Sales & Forecast: 2013-2023 Table 5.1.11.a: Afinitor Sales: 2008-2012 Table 5.1.11.b: 2011 - 2012 Afinitor Sales Geographic Breakdown ($ m) Table 5.1.11.c: Afinitor Sales & Forecast: 2013-2023 Table 5.1.12.a: Xgeva Sales: 2008-2012 Table 5.1.12.b: 2011 - 2012 Xgeva Sales Geographic Breakdown ($ m) Table 5.1.12.c: Xgeva Sales & Forecast: 2013-2023 Table 5.1.13.a: Yervoy Sales: 2011-2012 Table 5.1.13.b: 2011 - 2012 Yervoy Sales Geographic Breakdown ($ m) Table 5.1.13.c: Yervoy Sales & Forecast: 2013-2023 Table 5.1.14.a: Erbitux Sales BMS: 2008-2012 Table 5.1.14.b: Erbitux Sales Merck KGaA: 2008-2012 Table 5.1.14.c: Erbitux Sales & Forecast: 2013-2023 Table 5.2.a: Global Chemotherapy Market for Cancer Treatment: 2008-2012 Table 5.2.b Market Size & Forecast – Chemotherapy Market 2013-2023 Table 5.2.1.a: Alimta Sales: 2008-2012 Table 5.2.1.b: 2011 - 2012 Alimta Sales Geographic Breakdown ($ bn) Table 5.2.1.c: Alimta Sales & Forecast: 2013-2023 Table 5.2.2.a: Xeloda Sales: 2008-2012 Table 5.2.2.b: 2011 - 2012 Xeloda Sales Geographic Breakdown ($ m) Table 5.2.2.c: Xeloda Sales & Forecast: 2013-2023 Table 5.2.3.a: Eloxatin Sales: 2008-2012 Table 5.2.3.b: 2011 - 2012 Eloxatin Sales Geographic Breakdown ($ bn) Table 5.2.3.c: Eloxatin Sales & Forecast: 2013-2023 Table 5.2.4.a: Temodar Sales: 2008-2012 Table 5.2.4.b: Temodar Sales & Forecast: 2013-2023 Table 5.2.5.a: Vidaza Sales: 2008-2012 Table 5.2.5.b: Vidaza Sales & Forecast: 2013-2023 Table 5.2.6.a: Taxotere Sales: 2008-2012 Table 5.2.6.b: 2011 - 2012 Taxotere Sales Geographic Breakdown ($ bn) Table 5.2.6.c: Taxotere Sales & Forecast: 2013-2023 Table 5.2.7.a: Treanda Sales: 2008-2012 Table 5.2.7.b: Treanda Sales & Forecast: 2013-2023 Table 5.3 Market Size & Forecast – Immunotherapy Market 2013-2023 Table 5.3.1.a: Revlimid Sales: 2008-2012 Table 5.3.1.b: Revlimid Sales & Forecast: 2013-2023 Table 5.3.2.a: Gardasil Sales: 2008-2012 Table 5.3.2.b: Gardasil Sales & Forecast: 2013-2023 Table 5.3.3.a: Zometa Sales: 2008-2012 Table 5.3.3.b: 2011 - 2012 Zometa Sales Geographic Breakdown ($/m) Table 5.3.3.c: Zometa Sales & Forecast: 2013-2023 Table 5.3.4.a: Global Hormone Therapy Market for Cancer Treatment: 2008-2012 Table 5.3.4.b Market Size & Forecast – Hormone Therapy Market 2013-2023 Table 5.4.1.a: Faslodex Sales: 2008-2012 Table 5.4.1.b: 2011 - 2012 Faslodex Sales Geographic Breakdown ($ m) Table 5.4.1.c: Faslodex Sales & Forecast: 2013-2023 Table 5.4.2.a: Zoladex Sales: 2008-2012 T able5.4.2.b: 2011 - 2012 Zoladex Sales Geographic Breakdown ($ m) Table 5.4.2.c: Zoladex Sales & Forecast: 2013-2023able Table 5.4.3.a List of generic Anastrozole manufacturing companies in 1 mg tablet type Table 5.4.3.b: Arimidex Sales: 2008-2012 Table 5.4.3.c: 2011 - 2012 Arimidex Sales Geographic Breakdown ($ m) Table 5.4.3.d: Arimidex Sales & Forecast: 2013-2023 Table 5.4.4.a: Casodex Sales: 2008-2012 Table 5.4.4.b: 2011 - 2012 Casodex Sales Geographic Breakdown ($ m) Table 5.4.4.c: Casodex Sales & Forecast: 2013-2023 Table 5.4.5.a: Sandostatin Sales: 2008-2012 Table 5.4.5.b: 2011 - 2012 Sandostatin Sales Geographic Breakdown ($ m) Table 5.4.5.c: Sandostatin Sales & Forecast: 2013-2023 Table 6.1a Oncology Drug – Recent Approvals Table 6.1b Oncology Drug Pipeline – Top 5 Late-stage Cancer Drugs Table 6.1c Oncology Drug Pipeline – Top 10 Experimental Cancer Drugs Table 6.1d Oncology Drug Pipeline – Cancer Drugs Failures Table 7.1 Key Emerging Countries Population Forecasts, 2013, 2018 & 2023 Table 7.2 Key Cancer Drugs Patent Expirations Table 7.3 Revenue loss due to Generic Competition Table 7.4 Future Revenue loss due to Generic Competition Table 8.a: The Global Oncology Market Forecast 2013 -2023, by Country ($ bn) Table 8.b Key Countries CAGR 2013-2023 (%) Table 8.c Estimated Global Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%) Table8.d: Total Healthcare Spending and Healthcare Expenditure per Capita 2011, Sample countries ($/p/a) Table 8.1.1: The US Oncology Market Forecast 2013-2023 ($bn) Table 8.1.2 Estimated Rates of Cancer in the US / Survival Rate 2012 Table 8.2.1: The UK Oncology Market Forecast 2013-2023 ($bn) Table 8.2.2: The UK’s national CDF list Table 8.3.1: The French Oncology Market Forecast 2013-2023 ($ bn) Table 8.4.1: The German Oncology Market Forecast 2013-2023 ($ bn) Table 8.4.2: Germany Cancer Statistics Table 8.5.1: The Spanish Oncology Market Forecast 2013-2023 ($ bn) Table 8.6.1: The Italian Oncology Market Forecast 2013-2023 ($ bn) Table 8.6.2: Percentage of patient access to oncology medicines by Italian region Table 8.6.3: Major cancer drug prices in Italy (INCORRECT CHART BELOW) Table 8.7.1: The Japanese Oncology Market Forecast 2013-2023 ($ bn) Table 8.8.1: The ROW Oncology Market Forecast 2013-2023 ($ bn) Table 8.2.2: BRIC Population, Healthcare Expenditure per Capita Table 8.2.3 Estimated Oncology Market Share for Selected Countries 2013, 2018 and 2023 (%) Table 9.1.1. Amgen Oncology Product overview Table 9.1.2. Amgen Oncology Product pipeline Table 9.2.1 Arida Oncology Product overview Table 9.2.2 Product pipeline Table 9.3.1 Astellas Oncology Products Overview Table 9.3.2 Astellas Oncology Product Pipeline Table 9.4.1 AstraZeneca Oncology Product pipeline Table 9.5.1 Bayer healthcare pharmaceuticals Oncology Product overview Table 9.5.2 Bayer healthcare pharmaceuticals Oncology Product pipeline Table 9.6.1 Boehringer Ingelheim Oncology Product overview Table 9.6.2 Boehringer Ingelheim Oncology Product pipeline Table 9.7.1 Bristol-Myers Squibb Oncology Products Overview Table 9.7.2 Bristol-Myers Squibb Oncology Pipeline Projects Table 9.8.1 Celgene oncology Product overview Table 9.8.2 Celgene oncology Product pipeline Table 9.9.1 Eisai Co., Ltd. Oncology Product overview Table 9.9.2 Eisai Co., Ltd. Oncology Product pipeline Table 9.10.1 Eli Lilly & Co oncology Products Overview Table 9.10.2 Eli Lilly & Co oncology Pipeline Product Table 9.11.1 ImClone Systems Inc. Oncology Product pipeline Table 9.12.1 Exelixis Oncology Products Overview Table 9.12.2 Exelixis Oncology Pipeline Projects Table 9.13.1 GlaxoSmithKline Oncology Product overview Table 9.13.2 GlaxoSmithKline Oncology Product pipeline Table 9.13.3 GlaxoSmithKline Oncology Product Antigen-specific cancer immunotherapeutic (ASCI) Table 9.14.1 Merck Oncology Products Overview Table 9.14.2 Merck Oncology Merck Pipeline Table 9.15.1 Millennium Pharmaceuticals Oncology Product overview Table 9.15.2 Millennium Pharmaceuticals Oncology Product pipeline Table 9.16.1 Novartis Pharmaceuticals Oncology product overview Table 9.16.2 Novartis Pharmaceuticals Oncology Product pipeline Table 9.17.1 Onyx Pharmaceuticals Oncology Product overview Table 9.17.2 Onyx Pharmaceuticals Oncology Product pipeline Table 9.18.1 Pfizer Inc. Oncology Product overview Table 9.18.2 Pfizer Inc. Oncology Product Pipeline Table 9.19.1 Roche Oncology Products overview Table 9.19.2 Roche Oncology Product pipeline Table 9.20.1 Sanofi Oncology Product overview Table 9.20.2 Sanofi Oncology Product pipeline Table 9.21.1 Teva Pharmaceuticals Industries Oncology Product overview Table 9.21.2 Teva Pharmaceuticals Industries Oncology Product pipeline List of Figures Figure 188.8.131.52 Blood Cancer Type – Incidences Figure 184.108.40.206: Global Breakdown of types of Bone Cancer Figure2.1.11 Global Market Size as per Lung Cancer Type – Incidences Figure 2.1.12 Global Market Size as per Skin Cancer Type – Incidences Figure2.2.1a Global Cancer Market as per Incidences Figure2.2.2a Global Cancer Market by Mortality & Survival Figure 5.1.a: Global Targeted Therapy Market for Cancer Treatment: 2008-2012 Figure 5.1.b: 2012 Targeted Therapy Market by Major Drugs Figure 5.1.c: 2012 Other Targeted Therapy Drugs Market Share Figure 5.1d: Global Targeted Therapy Market for Cancer Treatment: 2013-2023 Figure 5.1.1.a: 2012 Rituxan Sales Geographic Breakdown Figure 5.1.1.b: Rituxan Sales: 2008-2012 Figure 5.1.1.c: Rituxan Sales & Forecast: 2013-2023 Figure 220.127.116.11: Herceptin Sales: 2008-2012 Figure 18.104.22.168: 2012 Herceptin Sales Geographic Breakdown Figure 22.214.171.124: Herceptin Sales & Forecast: 2013-2023 Figure 126.96.36.199: Avastin Sales: 2008-2012 Figure 188.8.131.52: 2012 Avastin Sales Geographic Breakdown Figure 184.108.40.206: Avastin Sales & Forecast: 2013-2023 Figure 220.127.116.11: Gleevec Sales: 2008-2012
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.